Pontillo G, Cocozza S, Lanzillo R, Borrelli P, De Rosa A, Brescia Morra V, Tedeschi E, PalmaG
* Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study (314 views)
Front Neurol (ISSN: 1664-2295, 1664-2295linking, 1664-2295print), 2017 Jun 19; 8: 294-294.
Impact Factor: 3.508
View    Export to BibTeX    Export to EndNote

Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V
* JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level (520 views)
Ther Clin Risk Manag (ISSN: 1178-203x), 2014 Oct 9; 10: 807-814.
Impact Factor: 1.469
View    Export to BibTeX    Export to EndNote

Clerico M, De Mercanti S, Versino E, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Amato L, Quarantelli M, Ghezzi A, Bianchi A, Baroncini D, Salemi G, Realmuto S, Ferro MT, Vitetta F, Donghia M, Paolicelli D, Trojano M, Durelli L
* Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study (361 views)
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2013 Oct; 19(11): N/D-N/D.
Impact Factor: 4.863
View    Export to BibTeX    Export to EndNote

Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L, Carotenuto A, Tedeschi G, Orefice G, Brescia Morra V
* Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice (441 views)
Neurol Sci (ISSN: 1590-1874, 1590-0187, 1590-3478), 2013 Apr; 34(4): 521-528.
Impact Factor: 0.38
View    Export to BibTeX    Export to EndNote

Clerico M, De Mercanti S, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Amato L, Quarantelli M, Ghezzi A, Bianchi A, Baroncini D, Gibbin M, Vargas J, Salemi G, Realmuto S, Ferrò MT, Vitetta F, Sola P, Paolicelli D, Trojano M, Durelli L
* Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study (342 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2013 Feb 12; 80: 197-197.
Impact Factor: 8.303
View    Export to BibTeX    Export to EndNote

Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V
* Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: A head-to-head retrospective study (514 views)
Acta Neurol Scand (ISSN: 0001-6314, 1600-0404), 2012 Nov; 126(5): 306-314.
Impact Factor: 2.474
View    Export to BibTeX    Export to EndNote

Clerico M, De Mercanti S, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Amato L, Quarantelli M, Ghezzi A, Bianchi A, Baroncini D, Gibbin M, Vargas J, Salemi G, Realmuto S, Ferrò MT, Vitetta F, Mascolo L, Paolicelli D, Trojano M, Durelli L
* Looking for the best therapeutical strategy after the 24th natalizumab administration. The TY-STOP study (413 views)
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2012 Oct; 18: 976-976.
Impact Factor: 4.472
View    Export to BibTeX    Export to EndNote